XM does not provide services to residents of the United States of America.
M
M

Morphosys

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Morphosys: Pichota and Lukas Gilgen replacing CEO And CFO

BRIEF-Morphosys: Pichota and Lukas Gilgen replacing CEO And CFO June 7 (Reuters) - MORPHOSYS AG MORG.DE : EQS-ADHOC: AD HOC: ARKADIUS PICHOTA AND LUKAS GILGEN APPOINTED TO MANAGEMENT BOARD OF MORPHOSYS AG REPLACING THE CURRENT CEO AND CFO Source text for Eikon: ID:nEQQh9gja Further company coverage: MORG.DE (Gdansk Newsroom)
M

Novartis Meets All Tender Offer Conditions To Acquire Morphosys

BRIEF-Novartis Meets All Tender Offer Conditions To Acquire Morphosys May 16 (Reuters) - NOVARTIS AG NOVN.S : NOVARTIS MEETS ALL TENDER OFFER CONDITIONS TO ACQUIRE MORPHOSYS AG FOR EUR 68 PER SHARE IN CASH SETTLEMENT OF SHARES TENDERED DURING INITIAL ACCEPTANCE PERIOD IS EXPECTED TO OCCUR ON 23 MAY 2024 Source text for Eikon: ID:nGNEcc97X3 Further
M
N

Novartis to buy radiology drug specialist Mariana for $1 billion

UPDATE 2-Novartis to buy radiology drug specialist Mariana for $1 billion Adds details on technology in paragraphs 5 and 6 By Andrey Sychev and Ludwig Burger May 2 (Reuters) - Novartis NOVN.S agreed to acquire U.S. radiopharmaceutical company Mariana Oncology for $1 billion upfront, boosting its portfolio of precision cancer treatments in development, the Swiss drug manufacturer said on Thursday.
M
N

Incyte misses quarterly profit on weak sales of lead drug

Incyte misses quarterly profit on weak sales of lead drug April 30 (Reuters) - Incyte Corp INCY.O on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%. The company is working on strengthening its pipeline to counter competition from newly approved drugs, which could impact sales of Jakafi, the company's biggest-selling drug, as it nears the loss of exclusivity later this decade.
I
M
N

Deals of the day-Mergers and acquisitions

Deals of the day-Mergers and acquisitions Adds Impossible foods, WeWork and Anglo American April 29 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 16:15 GMT on Monday: ** Impossible Foods, which makes meat alternatives from soy, is targeting a "liquidity event" that could include a public offering in the next two to three years, CEO Peter McGuinness told Reuters.
A
M
N
T
A

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.